Vascular Permeability Factor Lyophilized. Carrier free. AVOID FREEZE/THAW CYCLES. Recombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions. Biological activity: EC50 of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC). Purity: ≥95% by SDS-PAGE. Contaminants: Endotoxins: ≤100 pg/µg VEGF. Ref.: Hashimoto, G., et al. 2002. J. Biol. Chem. In Press. Soker, S., et al. 1998. Cell 92, 735. Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521. Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699. Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303. Brown, L., et al. 1992. Kidney International 42, 1457. Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275. Conn, G., et al. 1990. PNAS 87, 1323. Leung, D.W., et al. 1989. Science 246, 1306. |
